TISEO, Marcello
TISEO, Marcello
Dipartimento di Medicina e Chirurgia
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib
2013-01-01 Tiseo, M.; Rajan, A.; Thomas, A.; Giaccone, G.
'Turban-like' skull metastasis from pulmonary adenocarcinoma
2017-01-01 Mengoli, M. C.; Rossi, G.; Tiseo, M.; Barbieri, F.; Pifferi, M.; Bertolini, F.; Lococo, F.
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC
2022-01-01 Mazzaschi, G.; Moron Dalla Tor, L.; Balbi, M.; Milanese, G.; Tognazzi, D.; Lorusso, B.; Trentini, F.; Di Rienzo, G.; Verzè, M.; Pluchino, M.; Minari, R.; Leo, L.; Gnetti, L.; Bordi, P.; Leonetti, A.; Ampollini, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy
2021-01-01 Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M.
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
2021-01-01 Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC
2023-01-01 Mazzaschi, G.; Bocchialini, G.; Lorusso, B.; Pluchino, M.; Trentini, F.; Di Rienzo, G.; Cattadori, S.; Tor, L. Moron Dalla; Verzè, M.; Minari, R.; Bordi, P.; Leonetti, A.; D’Agnelli, S.; Milanese, G.; Leo, L.; Gnetti, L.; Roti, G.; Ampollini, L.; Quaini, F.; Sverzellati, N.; Tiseo, M.
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients
2020-01-01 Mazzaschi, G.; Minari, R.; Ferri, V.; Bordi, P.; Gnetti, L.; Bersanelli, M.; Cavazzoni, A.; Buti, S.; Leonetti, A.; Zecca, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mori, C.; Petronini, P. G.; Missale, G.; Quaini, F.; Tiseo, M.
209P: SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma
2016-01-01 Signorelli, D.; Proto, C.; Ganzinelli, M.; Russo, G. L.; Botta, L.; Trama, A.; Pasello, G.; Tiseo, M.; Pelosi, G.; Garassino, M.
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients
2023-01-01 Mazzaschi, G.; Cardinale, E.; Pluchino, M.; Monica, G.; Lorusso, B.; D'Agnelli, S.; Trentini, F.; Tamarozzi, P.; Dalla Tor, L. Moron; Verzè, M.; Minari, R.; Bordi, P.; Perrone, F.; Leonetti, A.; Gnetti, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors
2022-01-01 Mazzaschi, G.; Tamarozzi, P.; Lorusso, B.; Verzè, M.; Pluchino, M.; Trentini, F.; Dalla Valle, B.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Moron Dalla Tor, L.; Leo, L.; Milanese, G.; Balbi, M.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC
2016-01-01 Bordi, P.; Del Re, M.; Danesi, R.; Tiseo, M.
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients
2021-01-01 Mazzaschi, G.; Minari, R.; Gnetti, L.; Campanini, N.; Zielli, T.; Baucina, M.; Perrone, F.; Leonetti, A.; Quaini, F.; Tiseo, M.
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model
2023-01-01 Mazzaschi, G.; Dos Santos, M.; Bergeron, P.; Sitterle, L.; Gérbé de Thoré, M.; Liu, W.; Clémenson, C.; Meziani, L.; Bawa, O.; Leroy, A.; Sun, R.; Moron Dalla Tor, L.; Quaini, F.; Tiseo, M.; Milliat, F.; Robert, C.; Mondini, M.; Deutsch, E.
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?
2021-01-01 Leonetti, A.; Carbone, D.; Gregori, A.; Tiseo, M.; Peters, G. J.; Deng, D.; Giovannetti, E.
A metanalysis on cabozantinib and bone metastases: True story or commercial gimmick?
2020-01-01 Bersanelli, M.; Buti, S.; Ghidini, A.; Tiseo, M.; Petrelli, F.
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable
2019-01-01 Cortellini, Alessio; Bersanelli, Melissa; Buti, Sebastiano; Cannita, Katia; Santini, Daniele; Perrone, Fabiana; Giusti, Raffaele; Tiseo, Marcello; Michiara, Maria; Di Marino, Pietro; Tinari, Nicola; De Tursi, Michele; Zoratto, Federica; Veltri, Enzo; Marconcini, Riccardo; Malorgio, Francesco; Russano, Marco; Anesi, Cecilia; Zeppola, Tea; Filetti, Marco; Marchetti, Paolo; Botticelli, Andrea; Antonini Cappellini, Gian Carlo; De Galitiis, Federica; Vitale, Maria Giuseppa; Rastelli, Francesca; Pergolesi, Federica; Berardi, Rossana; Rinaldi, Silvia; Tudini, Marianna; Silva, Rosa Rita; Pireddu, Annagrazia; Atzori, Francesco; Chiari, Rita; Ricciuti, Biagio; De Giglio, Andrea; Iacono, Daniela; Gelibter, Alain; Occhipinti, Mario Alberto; Parisi, Alessandro; Porzio, Giampiero; Fargnoli, Maria Concetta; Ascierto, Paolo Antonio; Ficorella, Corrado; Natoli, Clara
A phase 1 study of mTORC1/2 inhibitor BI 860585 as a single agent or with exemestane or paclitaxel in patients with advanced solid tumors
2020-01-01 de Braud, F.; Machiels, J. -P. H.; Boggiani, D.; Rottey, S. W. H.; Duca, M.; Laruelle, M.; Salvagni, S.; Damian, S.; Lapeire, L. D. F.; Tiseo, M.; Dermine, A.; Ould-Kaci, M.; Braunger, J.; Rascher, J.; Fischer, D.; Hoefler, J.; Mariani, G. L.; Cresta, S.
A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer
2013-01-01 De Marinis, F.; Atmaca, A.; Tiseo, M.; Giuffreda, L.; Rossi, A.; Gebbia, V.; D'Antonio, C.; Zotto, L. D.; Al-Batran, S. -E.; Marsoni, S.; Wolf, M.
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale
2022-01-01 Andrini, Elisa; Lamberti, Giuseppe; Mazzoni, Francesca; Riccardi, Ferdinando; Bonetti, Andrea; Follador, Alessandro; Artioli, Fabrizio; Genova, Carlo; Barbieri, Fausto; Frassoldati, Antonio; Brighenti, Matteo; Colantonio, Ida; Pasello, Giulia; Ficorella, Corrado; Cinieri, Saverio; Tiseo, Marcello; Gelsomino, Francesco; Tognetto, Michele; Rihawi, Karim; Ardizzoni, Andrea
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine
2021-01-01 Ferlenghi, F; Scalvini, L; Vacondio, F; Castelli, R; Bozza, N; Marseglia, G; Rivara, S; Lodola, A; La Monica, S; Minari, R; Petronini, Pg; Alfieri, R; Tiseo, M; Mor, M.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib | 1-gen-2013 | Tiseo, M.; Rajan, A.; Thomas, A.; Giaccone, G. | |
'Turban-like' skull metastasis from pulmonary adenocarcinoma | 1-gen-2017 | Mengoli, M. C.; Rossi, G.; Tiseo, M.; Barbieri, F.; Pifferi, M.; Bertolini, F.; Lococo, F. | |
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC | 1-gen-2022 | Mazzaschi, G.; Moron Dalla Tor, L.; Balbi, M.; Milanese, G.; Tognazzi, D.; Lorusso, B.; Trentini, F.; Di Rienzo, G.; Verzè, M.; Pluchino, M.; Minari, R.; Leo, L.; Gnetti, L.; Bordi, P.; Leonetti, A.; Ampollini, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy | 1-gen-2021 | Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M. | |
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients | 1-gen-2021 | Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC | 1-gen-2023 | Mazzaschi, G.; Bocchialini, G.; Lorusso, B.; Pluchino, M.; Trentini, F.; Di Rienzo, G.; Cattadori, S.; Tor, L. Moron Dalla; Verzè, M.; Minari, R.; Bordi, P.; Leonetti, A.; D’Agnelli, S.; Milanese, G.; Leo, L.; Gnetti, L.; Roti, G.; Ampollini, L.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients | 1-gen-2020 | Mazzaschi, G.; Minari, R.; Ferri, V.; Bordi, P.; Gnetti, L.; Bersanelli, M.; Cavazzoni, A.; Buti, S.; Leonetti, A.; Zecca, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mori, C.; Petronini, P. G.; Missale, G.; Quaini, F.; Tiseo, M. | |
209P: SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma | 1-gen-2016 | Signorelli, D.; Proto, C.; Ganzinelli, M.; Russo, G. L.; Botta, L.; Trama, A.; Pasello, G.; Tiseo, M.; Pelosi, G.; Garassino, M. | |
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients | 1-gen-2023 | Mazzaschi, G.; Cardinale, E.; Pluchino, M.; Monica, G.; Lorusso, B.; D'Agnelli, S.; Trentini, F.; Tamarozzi, P.; Dalla Tor, L. Moron; Verzè, M.; Minari, R.; Bordi, P.; Perrone, F.; Leonetti, A.; Gnetti, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors | 1-gen-2022 | Mazzaschi, G.; Tamarozzi, P.; Lorusso, B.; Verzè, M.; Pluchino, M.; Trentini, F.; Dalla Valle, B.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Moron Dalla Tor, L.; Leo, L.; Milanese, G.; Balbi, M.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC | 1-gen-2016 | Bordi, P.; Del Re, M.; Danesi, R.; Tiseo, M. | |
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients | 1-gen-2021 | Mazzaschi, G.; Minari, R.; Gnetti, L.; Campanini, N.; Zielli, T.; Baucina, M.; Perrone, F.; Leonetti, A.; Quaini, F.; Tiseo, M. | |
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model | 1-gen-2023 | Mazzaschi, G.; Dos Santos, M.; Bergeron, P.; Sitterle, L.; Gérbé de Thoré, M.; Liu, W.; Clémenson, C.; Meziani, L.; Bawa, O.; Leroy, A.; Sun, R.; Moron Dalla Tor, L.; Quaini, F.; Tiseo, M.; Milliat, F.; Robert, C.; Mondini, M.; Deutsch, E. | |
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? | 1-gen-2021 | Leonetti, A.; Carbone, D.; Gregori, A.; Tiseo, M.; Peters, G. J.; Deng, D.; Giovannetti, E. | |
A metanalysis on cabozantinib and bone metastases: True story or commercial gimmick? | 1-gen-2020 | Bersanelli, M.; Buti, S.; Ghidini, A.; Tiseo, M.; Petrelli, F. | |
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable | 1-gen-2019 | Cortellini, Alessio; Bersanelli, Melissa; Buti, Sebastiano; Cannita, Katia; Santini, Daniele; Perrone, Fabiana; Giusti, Raffaele; Tiseo, Marcello; Michiara, Maria; Di Marino, Pietro; Tinari, Nicola; De Tursi, Michele; Zoratto, Federica; Veltri, Enzo; Marconcini, Riccardo; Malorgio, Francesco; Russano, Marco; Anesi, Cecilia; Zeppola, Tea; Filetti, Marco; Marchetti, Paolo; Botticelli, Andrea; Antonini Cappellini, Gian Carlo; De Galitiis, Federica; Vitale, Maria Giuseppa; Rastelli, Francesca; Pergolesi, Federica; Berardi, Rossana; Rinaldi, Silvia; Tudini, Marianna; Silva, Rosa Rita; Pireddu, Annagrazia; Atzori, Francesco; Chiari, Rita; Ricciuti, Biagio; De Giglio, Andrea; Iacono, Daniela; Gelibter, Alain; Occhipinti, Mario Alberto; Parisi, Alessandro; Porzio, Giampiero; Fargnoli, Maria Concetta; Ascierto, Paolo Antonio; Ficorella, Corrado; Natoli, Clara | |
A phase 1 study of mTORC1/2 inhibitor BI 860585 as a single agent or with exemestane or paclitaxel in patients with advanced solid tumors | 1-gen-2020 | de Braud, F.; Machiels, J. -P. H.; Boggiani, D.; Rottey, S. W. H.; Duca, M.; Laruelle, M.; Salvagni, S.; Damian, S.; Lapeire, L. D. F.; Tiseo, M.; Dermine, A.; Ould-Kaci, M.; Braunger, J.; Rascher, J.; Fischer, D.; Hoefler, J.; Mariani, G. L.; Cresta, S. | |
A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer | 1-gen-2013 | De Marinis, F.; Atmaca, A.; Tiseo, M.; Giuffreda, L.; Rossi, A.; Gebbia, V.; D'Antonio, C.; Zotto, L. D.; Al-Batran, S. -E.; Marsoni, S.; Wolf, M. | |
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale | 1-gen-2022 | Andrini, Elisa; Lamberti, Giuseppe; Mazzoni, Francesca; Riccardi, Ferdinando; Bonetti, Andrea; Follador, Alessandro; Artioli, Fabrizio; Genova, Carlo; Barbieri, Fausto; Frassoldati, Antonio; Brighenti, Matteo; Colantonio, Ida; Pasello, Giulia; Ficorella, Corrado; Cinieri, Saverio; Tiseo, Marcello; Gelsomino, Francesco; Tognetto, Michele; Rihawi, Karim; Ardizzoni, Andrea | |
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine | 1-gen-2021 | Ferlenghi, F; Scalvini, L; Vacondio, F; Castelli, R; Bozza, N; Marseglia, G; Rivara, S; Lodola, A; La Monica, S; Minari, R; Petronini, Pg; Alfieri, R; Tiseo, M; Mor, M. |